{"id":886773,"date":"2025-09-16T12:11:11","date_gmt":"2025-09-16T16:11:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\/"},"modified":"2025-09-16T12:11:11","modified_gmt":"2025-09-16T16:11:11","slug":"allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\/","title":{"rendered":"Allure Magazine Honors Arcutis\u2019 ZORYVE\u00ae (roflumilast) with Prestigious Best of Beauty Breakthrough Award"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>First FDA-approved medication for atopic dermatitis (eczema), plaque psoriasis, and seborrheic dermatitis to win prominent \u201cBreakthrough Award\u201d<\/li>\n<li>ZORYVE is the number one prescribed branded topical therapy across three major inflammatory dermatoses combined\u2014eczema, plaque psoriasis, and seborrheic dermatitis<\/li>\n<li>Cream and leave-in foam options are uniquely formulated to be used anywhere on the body once per day and on diverse skin and hair types<\/li>\n<li>ZORYVE was shown to be safe and well-tolerated and to provide rapid and reliable symptom relief and has been chosen by healthcare providers over 1 million times<\/li>\n<\/ul>\n<p>WESTLAKE VILLAGE, Calif., Sept.  16, 2025  (GLOBE NEWSWIRE) &#8212; Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company dedicated to developing meaningful innovations in immuno-dermatology, today announced that ZORYVE was presented with a\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sWXnUZQR3zFJe3TiJF-XLe5ED0baDP7-6lvG8Sq5HLThUcM_Yr1LsgqlJw7sylU4D5dMknlJNYo-LuhSFugMFwMIWma2c8Jfvi8EJYLWCZ9yRQ0uo5f5LRXBxD0fvI7yn1hoNnWbG0qz-HsnoxQRtygmzbqZRGVoAlWuaZOojWw=\" rel=\"nofollow\" target=\"_blank\">2025 Best of Beauty Breakthrough Award<\/a> by <em>Allure <\/em>magazine<em>, <\/em>which is globally recognized as the most distinguished beauty award by industry professionals and consumers. ZORYVE is the first prescription topical medication for eczema, plaque psoriasis, and seborrheic dermatitis to win the prestigious <em>Allure<\/em> Best of Beauty Breakthrough Award, which highlights groundbreaking innovations transforming the skincare category.<\/p>\n<p>\u201cZORYVE earning the <em>Allure<\/em> Best of Beauty Breakthrough Award is a powerful acknowledgment of its truly unique profile in dermatology. ZORYVE stands apart in its versatility and safety profile, providing patients with a single, effective, and well-tolerated option that can be used across multiple inflammatory skin diseases and applied anywhere on the body. This recognition underscores not only innovation in topical drug delivery but also meaningful progress in addressing unmet patient care needs,\u201d said Adam Friedman, MD, FAAD, professor and chair of dermatology at The George Washington University School of Medicine &amp; Health Sciences<strong>.<\/strong><\/p>\n<p>ZORYVE is the number one prescribed branded topical therapy across three major inflammatory dermatoses combined\u2014eczema, plaque psoriasis, and seborrheic dermatitis.<\/p>\n<p>&#8220;We are thrilled that ZORYVE has been recognized with <em>Allure\u2019s <\/em>prestigious Best of Beauty Breakthrough Award, which celebrates truly first-of-its-kind innovation,&#8221; said Frank Watanabe, president and chief executive officer of Arcutis. &#8220;ZORYVE is a highly selective and potent phosphodiesterase-4 (PDE4) inhibitor with a unique, moisturizing formulation\u2014specifically designed without ingredients that could further compromise the fragile skin barrier in conditions like atopic dermatitis, psoriasis, and seborrheic dermatitis. By offering a safe, effective, and easy-to-use alternative to steroids and medicated shampoos, ZORYVE is redefining how inflammatory skin diseases are treated. This award is a powerful testament to the ingenuity of our team at Arcutis and our unwavering commitment to delivering advanced targeted topicals that raise the bar in dermatology.&#8221;<\/p>\n<p>ZORYVE is a once-daily, steroid-free topical foam or cream that can be used anywhere on the body, for any duration, and is suitable for all skin and hair types. ZORYVE\u2019s novel, water-based, non-greasy formulation has moisturizing properties and contains no penetration enhancers, ceramide-stripping properties, fragrances, ethanol, or propylene glycol.<\/p>\n<p>For more information including prescribing information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2mTLCEMH6B0DjUc-mJ1FpcQvkGXQSyAq8yOj5HS9ToHdMWrqlYjZWHSlBC2cvl0zlN697qkn3Fx4GhQOkg0odw==\" rel=\"nofollow\" target=\"_blank\">www.zoryve.com<\/a>.<\/p>\n<p>\n        <strong>About the <\/strong><br \/>\n        <strong><br \/>\n          <em>Allure<\/em><br \/>\n        <\/strong><br \/>\n        <strong> Best of Beauty Awards<\/strong>\n      <\/p>\n<p>For 29 years, the <em>Allure<\/em> Best of Beauty Awards have sought to highlight the best beauty products between skin, body, hair, makeup, nails, tools, and scent. The products are rigorously tested, and the editors consult a panel of professional judges\u2014including top dermatologists, makeup artists, hairstylists, and cosmetic chemists\u2014to determine which products are the best. The Best of Beauty Breakthrough is a distinct category of the awards that seeks the most revolutionary beauty products over the same categories. Fewer than 10 products typically win the Breakthrough category, making it one of the most selective and prestigious honors in beauty, reserved for game-changing innovations that have real impact on the lives of consumers.<\/p>\n<p>\n        <strong>About ZORYVE<\/strong><br \/>\n        <sup>\u00ae<\/sup><br \/>\n        <strong> (roflumilast)<\/strong>\u00a0<br \/>ZORYVE is the number one prescribed branded topical therapy across three major inflammatory dermatoses combined\u2014eczema, seborrheic dermatitis, and plaque psoriasis.\u00a0ZORYVE is a next-generation, highly potent, and selective topical PDE4 inhibitor. PDE4, an established target in dermatology, is an intracellular enzyme that increases the production of pro-inflammatory mediators and decreases the production of anti-inflammatory mediators.<\/p>\n<p>ZORYVE cream 0.3% is approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of plaque psoriasis, including intertriginous areas, in patients 6 years of age and older. ZORYVE cream 0.15% is approved by the FDA for the topical treatment of mild to moderate atopic dermatitis in patients 6 years of age and older. In 2024, ZORYVE cream 0.15% was awarded\u00a0<em>Glamour\u2019s<\/em>\u00a0Beauty and Wellness Award for \u201cEczema Product.\u201d ZORYVE topical foam 0.3% is uniquely formulated for use anywhere on the body, including hair-bearing areas, and is indicated for the treatment of plaque psoriasis of the scalp and body in patients 12 years of age and older, as well as seborrheic dermatitis in patients 9 years of age and older. Recently, both ZORYVE cream 0.3% and ZORYVE foam 0.3% were awarded the National Psoriasis Foundation\u2019s Seal of Recognition\u2014the first FDA-approved product to receive the honor.<\/p>\n<p>\n        <strong>INDICATIONS\u00a0<\/strong><br \/>\n        <br \/>ZORYVE topical foam, 0.3%, is indicated for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older.\u00a0<\/p>\n<p>ZORYVE topical foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.<\/p>\n<p>ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older.<\/p>\n<p>ZORYVE cream, 0.15%, is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older.\u00a0<\/p>\n<p>\n        <strong>IMPORTANT SAFETY INFORMATION<\/strong>\u00a0\u00a0\u00a0<br \/>ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).\u00a0\u00a0<\/p>\n<p>\n        <strong>Flammability<\/strong>:\u00a0The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application.\u00a0<\/p>\n<p>The most common adverse reactions (\u22651%) for ZORYVE foam 0.3% for plaque psoriasis include headache (3.1%), diarrhea (2.5%), nausea (1.7%), and nasopharyngitis (1.3%).\u00a0<\/p>\n<p>The most common adverse reactions (\u22651%) for ZORYVE foam 0.3% for seborrheic dermatitis include nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).\u00a0<\/p>\n<p>The most common adverse reactions (\u22651%) for ZORYVE cream 0.3% for plaque psoriasis include diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%).\u00a0<\/p>\n<p>The most common adverse reactions (\u22651%) for ZORYVE cream 0.15% for atopic dermatitis include headache (2.9%), nausea (1.9%), application site pain (1.5%), diarrhea (1.5%), and vomiting (1.5%).\u00a0<\/p>\n<p>ZORYVE is for topical use only and not for ophthalmic, oral, or intravaginal use.<\/p>\n<p>Please see full\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8FrSD08_bAwxvZPXTgmbGiG2c_BGHVPTbZQNiE3zKZIEpj6VPj3GohmpelvwSDxIpC4zHrflcTGVX7dR0nJf5dod3DcdQICyiDrTD1ccrrO0BTLAOuG1y5xnR4b_lWg3WEXRRBhrT2Qvci7iCfi8rQsinGunjeDoOvDstiWmWJnRm9Uya_Jt7EPr1zZsbC1tctQi9uIsabby4qdWyvs-vsc-UKxS2lpgEGgT4QKYhzVTfgDxB59K7R41bp8y7pr-nUhdphuGx1kBGUjsuHxSjka6MC2C_CZJ9YJHBxmmrZ0=\" rel=\"nofollow\" target=\"_blank\"><strong>Prescribing Information<\/strong><\/a>\u00a0for ZORYVE cream and full\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8FrSD08_bAwxvZPXTgmbGiG2c_BGHVPTbZQNiE3zKZKPn4Y54f4TQb4P-DF7vAMwxAKBt14ly4g2vZmiwMPu2Eco4IDspLVJRgpre22Qmkhs1WmtMeOtMlLm1vTUIhO-K9YTuLH-q9sTXS2kPEtkvCJ5zF7qSipmR_qaeVGLBqHmRaxZx_zGEivTMjepnPELAWApzSFr78B4Ok2kGxGwrsGeXdmyI-iwi-cBm4gSbCH6LCo52DvZ6V6N1dk8-PxZWR2t-4DyxAAi43ULLbSDDYmjiir-npYDSSorvuguSk0=\" rel=\"nofollow\" target=\"_blank\"><strong>Prescribing Information<\/strong><\/a>\u00a0for ZORYVE foam.<\/p>\n<p>\n        <strong>About Arcutis<\/strong>\u00a0<br \/>Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced, targeted topicals approved to treat three major inflammatory skin diseases. Arcutis\u2019 unique dermatology development platform coupled with our dermatology expertise allows us to invent differentiated therapies against biologically validated targets and has produced a robust pipeline with multiple follow-on clinical programs for a range of inflammatory dermatological conditions. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L50zezdBr_MpNdRdwKhysdotekBKg5-c2wYS2uyOt3KamMA9hqtokT9lbOByGg4RhMVvOeManwOUxiKX1AGXdAvcCHUkollV80v4HrylsieNdTkQK8vt68mLvVCvIXrPucJpU46KnTVwMv0TIy7EsWnwf15NDRVyZVGoL15g0oS3oOsN8JijLCZRUkIr-ptif0Vp_eEamq6vUw_j3X-C4-B-JSV-iAWBzAFDlJ2f7687dY9OaSjjCG6kgU1fAWG-_hqvZeOqm96-_JWrK3UZkA==\" rel=\"nofollow\" target=\"_blank\">www.arcutis.com<\/a>\u00a0or follow Arcutis on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9VORq45Ssib02eRm0qIbe5UKr7jr_NFr_kB0M2_DweIaGWPvcboC8rOYfpJbheR26F_FkiBRmVYll7vjnZecY1Pb4h6mhZlEgVjyc1eF2UxkOonw_eOO_FtF0Md8QtSHWsS20W03rSS4Es0YoFC2ynfdFrsS2DWnMBLuHwDkGmklaHjmkbPF-vTcjisewd3q8qWfr_e0CcTswwhx1YF4KoaqYRn6Fn6oLPsixodFk2D5N1TJqhxTvPeEjaqAeaWIJH_Djtm6bUbalsuJCG0Wdw==\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8xAsZUoA4jpokc5df9735B9ZNAa5wMO5CfliTtF7yzuSFyBKvH83YgnZUMmw-C80KJ8fxMtsJSNPhDPtV1z-uTtKQ5Ujy3g8IRU1MOqX1s2ozVfeUIZsajDU4Ao7-RcOO5ycLUCtSFtEfF5apLomuJtBvgWLqfaKHNSejsL06sOZ67thVcRFjYv9pvJLtkpCstueKCUoBJnik6oexXRYdKa4EGVZoCAhcQMsy0JYtsLU7EdfJQ6eaiAB0FANOx8G\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JsaNxgQshwRk-9T7IEMvXeM6m4z2yhdabV3WFe9TfTk742sZNy6Yzu4g0EYf1KFPbA6QbrLbawFEtpmvCdF9GnhCZ3W-q23L1fngJI0E1BtgwZHUOVxL0bigReIOwEagjhyr3vEybzOdcnvTy86EeZV9yeOsBYbO_Omph1AbDjyChzxOJ0xdBRawizA2l36m_8tQvTOVVhdYbBVc40wvauW6cph19qZqUavWDgdMJwUIPsUvH8l5571_5BGsh4oL\" rel=\"nofollow\" target=\"_blank\">Instagram<\/a>, and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=I-wtKmfNc3wKhKhJqkruKBQyRihVp9a84IY0n2UwOBDI-ft0ygQst5tpE4xa4V5Wy6P2lF6RW7wgG6aVtadfHOPfofoS-a7Z-S3zBbfiplHp6pkJSHf9p4NPqIhoYJktlTzHugapO1_ztH38HADCsTTxitzHGi0F6Ticy2LtkzoPYP7Dfkpm8eb7xw6xJsasHkAe8GarN-DU-CEHoRrtGg==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.\u00a0<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\u00a0<br \/>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company\u2019s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the potential real-world use of ZORYVE and the potential for ZORYVE cream or foam to advance the standard of care in eczema, plaque psoriasis, and seborrheic dermatitis. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the \u201cRisk Factors\u201d section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.\u00a0<\/p>\n<p>\n        <strong>Contacts<\/strong><br \/>\n        <br \/>\n        <strong>Media<\/strong><br \/>\n        <br \/>Amanda Sheldon, Head of Corporate Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RSA3iNMKH_NSO3DnhYNJz1DYpJv2eQRIwncmPRhIopd8yMWVLOzG_xG3yONtGI8PlKHEal7P2veBCcsSHAgeajnIVInyaHZcCeIahnzCaBA=\" rel=\"nofollow\" target=\"_blank\">media@arcutis.com<\/a><\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Brian Schoelkopf, Head of Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_JFRdWQU-ObvtgQNxNYMmLAr4RAisWC7GLOUsR1rvIZyaInSHPf1MAZXOERR0NPwQ6ZG_UR6QMqAJXisPD76FA==\" rel=\"nofollow\" target=\"_blank\">ir@arcutis.com<\/a><\/p>\n<p>Photos accompanying this announcement\u00a0are available at:\u00a0<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8VsyF1fHKbcJEwrNeBGAylck2WuGSO__-CO7ovPcPbactsvz0j1z7wUodmKg_zt8Oqbw-i5Yuf61oERhGxZNGx4ourtMRYeDIMGoy-pXdeeIGHWrTpClUfeW9feBSHdw2PbO4b7NYLuKmH1HA8FD1WDkJyCkGJl6aIhX9LRa8-HPPZH3EbGpSsMoiDOrmncGT-94diY1SkXg0WUDR_UJLk-aCt4osIm7-1necwOuDSSE5HeL56w4PmDC5m4EqSf9xuzhLARBLdJo4wZUF5kVnQ==\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/b1e80f99-8d1a-4da3-97c0-d3d2b7f4781a<\/a>\n      <\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8VsyF1fHKbcJEwrNeBGAylck2WuGSO__-CO7ovPcPbactsvz0j1z7wUodmKg_zt8hSkFnu9YkB6VBF8q0MmkFa5FaQN0C-RYoK98DB4LxZYXfswbBOuuD1zm5uFfCi83jckk-fmlUmT8N_Ch99-WBiiEOirWHNE2eqsX3njSss1cAYxNrTdsOx7EBppZR2ucy0JTYMO0a9LIhAyq6l4Ec_icdsE0yUDb0zxkRyV71oWGyRl5zTKn7KXZOGZPqsuRLIq7SAC8LRsvqTWWhk7y9Q==\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/2bbf3607-605b-47cc-9780-943965c03fa0<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyOTc3OSM3MTQ3MzIyIzIxOTQwNTA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MThmMDBkMDctN2Q1YS00N2Q1LTk2ODMtN2NlNjRmMzBmOGMxLTEyMDU2MDMtMjAyNS0wOS0xNi1lbg==\/tiny\/Arcutis-Biotherapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>First FDA-approved medication for atopic dermatitis (eczema), plaque psoriasis, and seborrheic dermatitis to win prominent \u201cBreakthrough Award\u201d ZORYVE is the number one prescribed branded topical therapy across three major inflammatory dermatoses combined\u2014eczema, plaque psoriasis, and seborrheic dermatitis Cream and leave-in foam options are uniquely formulated to be used anywhere on the body once per day and on diverse skin and hair types ZORYVE was shown to be safe and well-tolerated and to provide rapid and reliable symptom relief and has been chosen by healthcare providers over 1 million times WESTLAKE VILLAGE, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) &#8212; Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company dedicated to developing meaningful innovations in immuno-dermatology, today announced that ZORYVE was presented &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Allure Magazine Honors Arcutis\u2019 ZORYVE\u00ae (roflumilast) with Prestigious Best of Beauty Breakthrough Award&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-886773","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Allure Magazine Honors Arcutis\u2019 ZORYVE\u00ae (roflumilast) with Prestigious Best of Beauty Breakthrough Award - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Allure Magazine Honors Arcutis\u2019 ZORYVE\u00ae (roflumilast) with Prestigious Best of Beauty Breakthrough Award - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"First FDA-approved medication for atopic dermatitis (eczema), plaque psoriasis, and seborrheic dermatitis to win prominent \u201cBreakthrough Award\u201d ZORYVE is the number one prescribed branded topical therapy across three major inflammatory dermatoses combined\u2014eczema, plaque psoriasis, and seborrheic dermatitis Cream and leave-in foam options are uniquely formulated to be used anywhere on the body once per day and on diverse skin and hair types ZORYVE was shown to be safe and well-tolerated and to provide rapid and reliable symptom relief and has been chosen by healthcare providers over 1 million times WESTLAKE VILLAGE, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) &#8212; Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company dedicated to developing meaningful innovations in immuno-dermatology, today announced that ZORYVE was presented &hellip; Continue reading &quot;Allure Magazine Honors Arcutis\u2019 ZORYVE\u00ae (roflumilast) with Prestigious Best of Beauty Breakthrough Award&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-16T16:11:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyOTc3OSM3MTQ3MzIyIzIxOTQwNTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Allure Magazine Honors Arcutis\u2019 ZORYVE\u00ae (roflumilast) with Prestigious Best of Beauty Breakthrough Award\",\"datePublished\":\"2025-09-16T16:11:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\\\/\"},\"wordCount\":1480,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyOTc3OSM3MTQ3MzIyIzIxOTQwNTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\\\/\",\"name\":\"Allure Magazine Honors Arcutis\u2019 ZORYVE\u00ae (roflumilast) with Prestigious Best of Beauty Breakthrough Award - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyOTc3OSM3MTQ3MzIyIzIxOTQwNTA=\",\"datePublished\":\"2025-09-16T16:11:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyOTc3OSM3MTQ3MzIyIzIxOTQwNTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyOTc3OSM3MTQ3MzIyIzIxOTQwNTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Allure Magazine Honors Arcutis\u2019 ZORYVE\u00ae (roflumilast) with Prestigious Best of Beauty Breakthrough Award\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Allure Magazine Honors Arcutis\u2019 ZORYVE\u00ae (roflumilast) with Prestigious Best of Beauty Breakthrough Award - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\/","og_locale":"en_US","og_type":"article","og_title":"Allure Magazine Honors Arcutis\u2019 ZORYVE\u00ae (roflumilast) with Prestigious Best of Beauty Breakthrough Award - Market Newsdesk","og_description":"First FDA-approved medication for atopic dermatitis (eczema), plaque psoriasis, and seborrheic dermatitis to win prominent \u201cBreakthrough Award\u201d ZORYVE is the number one prescribed branded topical therapy across three major inflammatory dermatoses combined\u2014eczema, plaque psoriasis, and seborrheic dermatitis Cream and leave-in foam options are uniquely formulated to be used anywhere on the body once per day and on diverse skin and hair types ZORYVE was shown to be safe and well-tolerated and to provide rapid and reliable symptom relief and has been chosen by healthcare providers over 1 million times WESTLAKE VILLAGE, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) &#8212; Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company dedicated to developing meaningful innovations in immuno-dermatology, today announced that ZORYVE was presented &hellip; Continue reading \"Allure Magazine Honors Arcutis\u2019 ZORYVE\u00ae (roflumilast) with Prestigious Best of Beauty Breakthrough Award\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-16T16:11:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyOTc3OSM3MTQ3MzIyIzIxOTQwNTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Allure Magazine Honors Arcutis\u2019 ZORYVE\u00ae (roflumilast) with Prestigious Best of Beauty Breakthrough Award","datePublished":"2025-09-16T16:11:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\/"},"wordCount":1480,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyOTc3OSM3MTQ3MzIyIzIxOTQwNTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\/","name":"Allure Magazine Honors Arcutis\u2019 ZORYVE\u00ae (roflumilast) with Prestigious Best of Beauty Breakthrough Award - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyOTc3OSM3MTQ3MzIyIzIxOTQwNTA=","datePublished":"2025-09-16T16:11:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyOTc3OSM3MTQ3MzIyIzIxOTQwNTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyOTc3OSM3MTQ3MzIyIzIxOTQwNTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allure-magazine-honors-arcutis-zoryve-roflumilast-with-prestigious-best-of-beauty-breakthrough-award\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Allure Magazine Honors Arcutis\u2019 ZORYVE\u00ae (roflumilast) with Prestigious Best of Beauty Breakthrough Award"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/886773","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=886773"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/886773\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=886773"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=886773"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=886773"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}